Sepsis, defined as an infection accompanied by inflammation, is a complex disease process wherein the body's response to a pathogen is amplified far beyond the initial site of infection. The process begins when pathogen-associated molecular patterns on the bacteria or other pathogens induce an inflammatory cascade in the host. In the United States, it is estimated that every minute a patient with severe sepsis or septic shock presents to an emergency department and that > 751 000 cases of severe sepsis occur annually, resulting in an estimated 215 000 deaths. A rapid progression of illness severity from sepsis to severe sepsis to septic shock frequently occurs, driven by the body's inflammatory and anti-inflammatory responses to a pathogen, making sepsis a condition requiring timely intervention. The clinical management of severe sepsis and septic shock has evolved dramatically over the past decade and these new therapeutic approaches have been built on a deeper understanding of the natural evolution of sepsis. This article examines the underlying pathophysiological mechanisms of sepsis to help explain the clinical signs and symptoms manifested by severe sepsis patients. It also examines the significance of current proposed treatment strategies, including early goal-directed therapy, from a pathophysiological and inflammatory perspective.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3810/hp.2011.08.585 | DOI Listing |
Pak J Pharm Sci
January 2025
Department of Intensive Care Medicine, Putuo Central Hospital, Shanghai, China.
This study aimed to use meta-analytic techniques to evaluate aspirin's safety and effectiveness in treating elderly patients with sepsis. We searched PubMed, Embase, The Cochrane Library, Web of Science and Medline databases for relevant literature, screened and extracted key data and Stata 12.0 was used for comprehensive analysis.
View Article and Find Full Text PDFXi Bao Yu Fen Zi Mian Yi Xue Za Zhi
January 2025
Department of Neonatology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200062, China. *Corresponding author, E-mail:
Necrotizing enterocolitis (NEC) is an intestinal inflammatory and necrotic disease seen in premature infants, and remains the leading cause of death resulted from gastrointestinal diseases in premature infants. The specific pathogenesis of NEC is still unclear. In recent years, a lot of studies have reported that Toll-like receptor 4 (TLR4) plays a key role in the pathogenesis of NEC.
View Article and Find Full Text PDFBMC Anesthesiol
January 2025
Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, 210009, China.
Background: Patients with sepsis in the intensive care unit (ICU) often experience rapid muscle loss. The urea-to-creatinine ratio (UCR) is thought to reflect muscle breakdown (creatinine) and catabolism (urea) and is commonly used to assess nutritional and metabolic status. This study aimed to investigate whether changes in UCR (ΔUCR) can predict the development of rapid muscle loss in patients with sepsis.
View Article and Find Full Text PDFMed Intensiva (Engl Ed)
January 2025
Intensive Care Unit, Adesh Medical College and Hospital, NH44, Mohri, Ambala, Haryana-136135, India; Department of Anaesthesiology and Critical Care, Command Hospital (NC), Udhampur 182101, India. Electronic address:
Lancet Child Adolesc Health
January 2025
Department of Infectious Diseases, Alder Hey Children's NHS Foundation Trust, Liverpool, UK; Department of Clinical Infection, Microbiology, and Immunology, Institute of Infection, Veterinary, and Ecological Sciences, University of Liverpool, Liverpool, UK. Electronic address:
Background: Procalcitonin is a rapid response biomarker specific for bacterial infection, which is not routinely used in the UK National Health Service. We aimed to assess whether using a procalcitonin-guided algorithm would safely reduce the duration of antibiotic therapy compared with usual care, in which C-reactive protein is the commonly used biomarker.
Methods: The BATCH trial was a pragmatic, multicentre, open-label, parallel, two-arm, individually randomised, controlled trial conducted in 15 hospitals in England and Wales.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!